GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arno Therapeutics Inc (OTCPK:ARNI) » Definitions » 5-Day RSI

Arno Therapeutics (Arno Therapeutics) 5-Day RSI : 100.00 (As of May. 06, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Arno Therapeutics 5-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-05-06), Arno Therapeutics's 5-Day RSI is 100.00.

The industry rank for Arno Therapeutics's 5-Day RSI or its related term are showing as below:

ARNI's 5-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 55.415 vs ARNI: 100.00

Competitive Comparison of Arno Therapeutics's 5-Day RSI

For the Biotechnology subindustry, Arno Therapeutics's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arno Therapeutics's 5-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arno Therapeutics's 5-Day RSI distribution charts can be found below:

* The bar in red indicates where Arno Therapeutics's 5-Day RSI falls into.



Arno Therapeutics  (OTCPK:ARNI) 5-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arno Therapeutics  (OTCPK:ARNI) 5-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Arno Therapeutics 5-Day RSI Related Terms

Thank you for viewing the detailed overview of Arno Therapeutics's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Arno Therapeutics (Arno Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
200 Route 31 North, Suite 104, Flemington, NJ, USA, 08822
Arno Therapeutics Inc operates as a biopharmaceutical company. It develops drug candidates to treat patients with cancer and other life-threatening diseases. It develops pre-clinical and clinical-stage product under the following name: Onapristone, AR-42, and AR-12. Onapristone is indicated for endometrial, prostate and breast cancer indications, AR-42 is provided for hematological malignancies and solid tumors indications and AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets.
Executives
S Donald Sussman other: See Footnote 1 888 EAST LAS OLAS BLVD, SUITE 710, FORT LAUDERDALE FL 33301
David M Tanen director, officer: Secretary TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022
Tomer Kariv director C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Arie Belldegrun director UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Alexander A Zukiwski director, officer: Chief Executive Officer & CMO 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Jay Moorin director C/O PROQUEST INVESTMENTS, L.P, 2430 VANDERBILT BEACH ROAD, #108 - 190, NAPLES FL 34109
Lawrence A Kenyon officer: Chief Financial Officer C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Glenn R. Mattes director, officer: President & CEO 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Randy H Thurman director 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Wexford Gp Llc other: No longer own 10% of Issuer C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH CT 33401
Joseph Jacobs other: No longer own 10% of Issuer C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Capital Lp other: No longer own 10% of Issuer 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Charles E Davidson other: No longer own 10% of Issuer C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Ran Nussbaum 10 percent owner C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Brian Lenz officer: Chief Financial Officer 65 COMMERCE WAY, HACKENSACK NJ 07601

Arno Therapeutics (Arno Therapeutics) Headlines

No Headlines